2027 ICD-10-CM Diagnosis Code C50.119Malignant neoplasm of central portion of unspecified female breast

ICD-10-CM Codes›C00–D49›C50›C50

ICD-10-CM C50.119
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

C50.119 is a billable ICD-10-CM diagnosis code for malignant neoplasm of central portion of unspecified female breast. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 582 through 583, 597 through 599. Coders also document this condition as carcinoma of central portion of breast. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Breast cancer - all other types.

For Medicare Advantage risk adjustment, C50.119 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
C50.119
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of central portion of unspecified female breast
Short Description
Malignant neoplasm of central portion of unsp female breast
Parent Code
C50.11
Malignant neoplasm of central portion of breast, female

Code Classification

ChapterC00–D49Neoplasms
SectionC50Malignant neoplasms of breast
CategoryC50Malignant neoplasm of breast
This CodeC50.119Malignant neoplasm of central portion of unspecified female breast

Medicare Risk Adjustment (HCC)Billing

C50.119 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 23— Prostate, Breast, and Other Cancers and Tumors
Payment HCC · PY 2027 one of 234 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.186
community, non-dual, aged · ranges 0.186–0.237 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 12
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 12 · ESRD (V21): HCC 12 · ESRD (V24): HCC 12
ESRD V21 weights: 0.046 dialysis, 0.156–0.194 functioning graft · ESRD V24 weights: 0.045 dialysis, 0.162–0.219 functioning graft
Part D (RxHCC)
RxHCC 22 — Prostate, Breast, Bladder, and Other Cancers and Tumors
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Carcinoma of central portion of breast
  • Infiltrating duct carcinoma of central portion of breast
  • Malignant neoplasm of central portion of breast
  • Primary infiltrating duct carcinoma of central portion of breast
  • Primary malignant neoplasm of central portion of breast
  • Sarcoma of breast
  • Sarcoma of central portion of breast

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to C50.119: its own notes plus those printed at C50 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.

Includes

Further defines, or gives examples of, the content of the category.

From C50 Malignant neoplasm of breast applies to 57 codes
  • connective tissue of breast
  • Paget's disease of breast
  • Paget's disease of nipple

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From C50 Malignant neoplasm of breast applies to 57 codes

Use Additional Code

Add a second code, after this one, to fully describe the condition.

From C50 Malignant neoplasm of breast applies to 57 codes
  • code to identify estrogen, and other hormones and factors receptor status (Z17.-)

Notes

General instructions on how these codes are used.

From Chapter 2 (C00-D49) Neoplasms applies to 1,730 codes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name C50.119, its category, or a range that includes it.

Applicable To 2

These notes mention C50.119.

  • Z80.3 Family history of malignant neoplasm of breast
    Conditions classifiable to C50.- names C50.-, which includes this code
  • Z85.3 Personal history of malignant neoplasm of breast
    Conditions classifiable to C50.- names C50.-, which includes this code

Excludes1 4

These codes carry an Excludes1 note naming C50.119: they are not reported together with it, unless the two conditions are unrelated.

  • C49 Malignant neoplasm of other connective and soft tissue
    malignant neoplasm of connective tissue of breast (C50.-) names C50.-, which includes this code
  • C49.3 Malignant neoplasm of connective and soft tissue of thorax
    malignant neoplasm of breast (C50.-) names C50.-, which includes this code
  • D05 Carcinoma in situ of breast
    malignant neoplasm of breast (C50.-) names C50.-, which includes this code
  • D05 Carcinoma in situ of breast
    Paget's disease of breast or nipple (C50.-) names C50.-, which includes this code

Code First 3

These codes say to code first a condition named in the note, and C50.119 is one of the conditions named.

  • D75.81 Myelofibrosis
    malignant neoplasm of breast (C50.-) names C50.-, which includes this code
  • Z17 Estrogen, and other hormones and factors receptor status
    malignant neoplasm of breast (C50.-) names C50.-, which includes this code
  • Z79.81 Long term (current) use of agents affecting estrogen receptors and estrogen levels
    malignant neoplasm of breast (C50.-) names C50.-, which includes this code

Code Also 2

These codes say C50.119 may also be needed to fully describe the condition. The note gives no sequencing direction.

  • D61.82 Myelophthisis
    malignant neoplasm of breast (C50.-) names C50.-, which includes this code
  • Z91.B Personal risk factor of exposure to diethylstilbestrol
    conditions classifiable to C50.- names C50.-, which includes this code

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO030
Breast cancer - all other types
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Malignant Breast Neoplasm

    a primary or metastatic malignant neoplasm involving the breast. the vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. malignant breast neoplasms occur more frequently in females than in males.

Patient EducationClinical

Breast Cancer

Breast cancer is a cancer that starts in breast tissue. It happens when cells in the breast change and grow out of control. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor.

The full article covers:

  • What is breast cancer?
  • What are the types of breast cancer?
  • What causes breast cancer?
  • Who is at risk for breast cancer?
  • What are the signs and symptoms of breast cancer?
  • How is breast cancer diagnosed?
  • What are the treatments for breast cancer?
  • Can breast cancer be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C50.119 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
174.1 Mal neo breast-central
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About C50.119Overview

What is the ICD-10 code for malignant neoplasm of central portion of unspecified female breast?

The ICD-10-CM code for malignant neoplasm of central portion of unspecified female breast is C50.119 (sometimes written as C50119). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is C50.119 (Malignant neoplasm of central portion of breast, female) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of central portion of unspecified female breast on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does C50.119 group to?

When malignant neoplasm of central portion of unspecified female breast is the principal diagnosis on an inpatient stay, it groups to MS-DRG 598, 582, 599, 597, 583, with relative weights from 0.6756 to 1.8014 depending on complications. Higher weights mean higher Medicare reimbursement.

Can C50.119 be reported with C44.501?

Not as a rule. The Excludes1 note at C50, which applies to C50.119, lists "skin of breast (C44.501, C44.511, C44.521, C44.591)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

Does C50.119 need an additional code?

When the condition applies, yes. The Use Additional Code note at C50, which applies to C50.119, reads: code to identify estrogen, and other hormones and factors receptor status (Z17.-). The additional code is reported after C50.119.

What HCC is C50.119?

C50.119 (malignant neoplasm of central portion of unspecified female breast) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.

Does C50.119 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, C50.119 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.